BioSpace News Archive

Soligenix, Inc. announced today that the Office of Orphan Products Development of the United States (U.S.) Food and Drug Administration (FDA) has granted orphan drug designation to the active ingredient hypericin for the treatment of T-cell lymphoma, extending the target population beyond cutaneous T-cell lymphoma (CTCL) as previously granted.

Invacare Corporation (NYSE:IVC) (“Invacare” or the “company”) will participate today in the 19th Annual Morgan Stanley Global Healthcare Conference with management available for 1x1 meetings with interested investors.

Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, today announced the appointment of Frank J. Hsu, M.D., as Chief Medical Officer, effective immediately

Rain Therapeutics Inc., a late-stage company developing precision oncology therapeutics, announced that Avanish Vellanki, co-founder, chairman and chief executive officer of Rain, will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually September 13-15, 2021.

Onconova Therapeutics, Inc. today announced that the Company will be participating in the H.C. Wainwright 23rd Annual Global Investment Conference taking place virtually September 13-15, 2021.

Catalyst Biosciences, Inc. (NASDAQ: CBIO) today presented data at the International Conference on Complement Therapeutics (ICCT), being held September 8-13, 2021.

Monopar Therapeutics Inc. today announced that Chandler D. Robinson, MD, Chief Executive Officer, is scheduled to present a Company overview at the following investor conferences in September: H.C. Wainwright 23rd Annual Global Investment Conference

Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ELX-02, a drug candidate intended to treat cystic fibrosis patients with nonsense mutations. ELX-02 is currently in Phase 2 clinical trials in CF patients affected by nonsense mutations in the CFTR (CF transmembrane conductance regulator) gene for whom there are no effective disease modifying therapies.

Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced the final clinical results from its Phase I clinical study of Lomecel-B in Hypoplastic Left Heart Syndrome (HLHS), a rare and life-threatening congenital heart disease.

AbbVie will participate in the Morgan Stanley Virtual 19th Annual Global Healthcare Conference on Wednesday, September 15, 2021.